BPC-157 + KPV
aka BPC-157/KPV blend · BPC-157 KPV
Mechanism
Pre-mixed blend of two component peptides marketed for tissue repair and inflammation. BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a gastric protective protein, studied in animals for tendon/ligament and GI healing, partly via the VEGFR2/angiogenesis pathway. KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-MSH that acts as an anti-inflammatory agent, primarily by inhibiting NF-kB signaling without melanocortin-receptor activation. Neither component is FDA-approved for human use, and there is no controlled human efficacy or safety data for this specific combination — the rationale is inferred from the individual grey-market research peptides.
Studied uses
- soft-tissue and tendon injury recovery (research only)
- gut inflammation and IBD-model support (research only)
- general anti-inflammatory and recovery stacking (research only)
Identification
| Typical dose | Vendor-dependent; component norms: BPC-157 250-500 mcg/day subcutaneous; KPV 200-500 mcg/day subcutaneous or oral. No validated combination dosing exists. |
|---|---|
| Half-life | BPC-157: disputed (under 30 minutes per most pharmacokinetic data); KPV: short (minutes to a few hours, not well characterized in humans) |
Safety
Not FDA-approved for human therapeutic use; sold as a research-only / grey-market blend. No combination-specific human safety data. Component risks are extrapolated from limited animal and early human research only. Not evaluated by WADA as a blend.
Vendors selling BPC-157 + KPV
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptidology | — | $129.99 | — | 89 |
Research
Background There is a concerning trend of misinformation of healthcare related content on social media. Recent studies have examined themes and narratives about Crohn's disease but have not quantitatively assessed the accuracy and quality of content on Instagram Reels.
source →